Shanghai Haohai Biological Technology Co., Ltd. (688366.SS) has a MoatMap StockRank of 51/100 based on Quality (62/100), Value (43/100), and Momentum (33/100) factor scores. The current signal is HOLD. Shanghai Haohai Biological is a high-margin medical aesthetics player, but it lacks direct alignment with our core macro themes and faces intensifying domestic competition.
Shanghai Haohai Biological Technology Co., Ltd. specializes in the research, development, and manufacture of biomedical materials, focusing on ophthalmology, medical aesthetics, wound care, and orthopedics. The company holds a dominant market position in China's intraocular lens (IOL) and ophthalmic viscoelastic agent markets, supported by strategic acquisitions along the global supply chain. It is a highly profitable, vertically integrated healthcare leader benefiting from China's aging population and growing aesthetic demand.
| Price | $4.67 |
| Market Cap | $1.1B |
| P/E (TTM) | 30.41 |
| P/E (Forward) | 13.24 |
| Price/Book | 1.39 |
| Return on Equity | 3.4% |
| Return on Invested Capital | 4.4% |
| Debt/Equity | 7.45 |
| Gross Margin | 68.3% |
| Operating Margin | 13.1% |
| Revenue Growth | -7.6% |
| Dividend Yield | 3.1% |
| Free Cash Flow | $2M |
Shanghai Haohai Biological Technology Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).